Pulmonary embolism presenting with acute abdominal pain in a girl with stable ankle fracture and inherited antithrombin deficiency

TO THE EDITOR: Pulmonary embolism (PE) is an uncommon disease in children and one of the presentations of venous thromboembolism (VTE). Usually, VTE in children and adolescents develops as a secondary complication of underlying factors such as venous catheterization, malignancy, infection, congenital heart disease, trauma, surgery, and inherited or acquired thrombophilia [1]. The relationship between VTE and certain types of inherited thrombophilia is well known in adults but remains inconclusive in pediatric patients, mainly due to lack of evidence [2, 3]. Among pediatric VTE patients in Western countries, the incidence of inherited thrombophilia, including factor V Leiden (G1691A), factor II (G20210A), protein C, protein S, and antithrombin (AT) deficiency, ranges from 10 to 59%. An especially higher prevalence of factor V Leiden was reported in the Caucasian population [1, 4, 5]. We...

REFERENCES
1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
2. Westermark P, Benson MD, Buxbaum JN, et al. A primer of amyloid nomenclature. Amyloid 2007;14:179-83.
3. Charlot M, Seldin DC, O’hara C, Skinner M, Sanchorawala V. Localized amyloidosis of the breast: a case series. Amyloid 2011;18:72-5.
4. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
5. Hayman SR, Lacy MQ, Kyle RA, Gertz MA. Primary systemic amyloidosis: a cause of malabsorption syndrome. Am J Med 2001;111:535-40.
6. Cowan AJ, Skinner M, Seldin DC, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica 2013;98:141-6.
7. Inayat F, Hurairah A. Duodenal amyloidosis masquerading as iron deficiency anemia. Cureus 2016;8:e725.
8. Syed U, Ching Companioni RA, Alkhawam H, Walfish A. Amyloidosis of the gastrointestinal tract and the liver: clinical context, diagnosis and management. Eur J Gastroenterol Hepatol 2016;28:1109-21.

Fig. 1. Computed tomography (CT) performed in the emergency room showed pulmonary emboli (arrow) in the right main pulmonary artery (A) and consolidation and ground glass opacity in the right lower lobe (B). Multifocal thrombi in the right common iliac vein (arrow) and inferior vena cava are visible in the abdominal CT scan (C). A small amount of thrombus is seen in the right popliteal vein, detected on CT venography (arrow) (D).
report a patient with combined deficiency of AT III and protein C, together with mutational analysis. To our knowledge, this is the first reported case with SERPINC1, c.1154-14G>A in Korea.

A 15-year-old girl developed chest discomfort 1 day prior to presentation, with progression to chest pain on the day of her visit to the emergency department. Chest computed tomography (CT) showed embolism of the right main pulmonary artery. Based on a history of PE 4 years prior, she was diagnosed with a recurrence. In the past episode, she visited the emergency department with the complaint of 8 hours of continuous, right upper and lower quadrant abdominal pain that worsened over time. She had been wearing a splint for 1 month following a simple fracture of the right ankle 2.5 months prior. Her grandmother had a history of PE and her father had a cerebral VTE. The subject’s father was on warfarin through the neurology outpatient clinic. Her grandmother recalled developing PE after colon surgery. Chest CT with contrast revealed PE involving the right pulmonary artery, except for the right middle lobe segmental artery, accompanied by consolidation and ground glass opacity (Fig. 1A, B). CT venography showed multifocal venous thrombi in the right common iliac vein and inferior vena cava (Fig. 1C), a small amount of venous thrombus in the right popliteal vein, and a fracture of the right distal tibia (Fig. 1D). Thrombophilic evaluation revealed normal levels, except for protein C and AT III (Table 1). Based on her family history, genetic analysis was performed for PROC, factor V Leiden (RS06Q), and prothrombin II (G20210A) mutations, but the results were negative. The patient's symptoms improved with anticoagulation (heparin), and she was discharged on warfarin.

Inherited AT deficiency is a well-known cause of thrombophilia and more than 300 mutations have been reported so far. Type I deficiency is characterized by a decrease in both antigen levels and functional AT activity. Type II deficiency is associated with decreased functional activity but almost normal antigen levels due to the presence of circulating dysfunctional AT variants [6]. Several cases with this type of mutation (c.1154-14G>A) involving a history of thromboembolic events with recurrences at a young age have been reported since 1991, and have been categorized as type I AT deficiency [7]. Jochmans et al. [8] demonstrated that the c.1154-14G>A mutation showed a 12-bp insertion of intron 5, just ahead of exon 6. Subsequently, a 12-bp insertion was thought to have created a new splice site to form an unstable protein with 4 extra amino acids.

Our patient had a risk factor, i.e., the history of a right ankle fracture 2.5 months prior. Therefore, she was predisposed to prolonged immobilization. Apart from acquired thrombophilic risk factors, AT and protein C levels were simultaneously reduced in the 2 episodes of PE and heterozygosity for the SERPINC1 gene was detected by mutational analysis. However, the PROC mutation was not detected by direct sequencing, even though the protein C level was reduced. The direct sequencing method is known to have PROC gene coverage of over 99%. Our patient had multiple risk factors including prolonged immobilization, inherited AT deficiency, and protein C deficiency. There are some anecdotal reports of combined AT and protein C deficiency [9, 10].

Of interest is that the patient initially presented with right abdominal pain; this is extremely rare in children.

Laboratory findings were consistent with those of the previous event in which decreased levels of protein C and AT III (Table 1) were observed. Therefore, at this time, the antithrombin gene for SERPINC1 and PROC, was reevaluated. A heterozygous variant of SERPINC1 splice site at -14 in intron 5 (c.1154-14G>A) was detected (Fig. 2). As the patient’s father, who had a history of VTE, was unwilling to undergo genetic evaluation, familial penetrance could not be confirmed.

AT, encoded by the SERPINC1 gene, is the most important naturally-occurring anticoagulant in the plasma and is a major inhibitor of activated coagulation factors IIa and Xa. Inherited AT deficiency is associated with an increased risk of VTE. AT deficiency is associated with decreased functional activity but almost normal antigen levels due to the presence of circulating dysfunctional AT variants [6]. Several cases with this type of mutation (c.1154-14G>A) involving a history of thromboembolic events with recurrences at a young age have been reported since 1991, and have been categorized as type I AT deficiency [7]. Jochmans et al. [8] demonstrated that the c.1154-14G>A mutation showed a 12-bp insertion of intron 5, just ahead of exon 6. Subsequently, a 12-bp insertion was thought to have created a new splice site to form an unstable protein with 4 extra amino acids.

Our patient had a risk factor, i.e., the history of a right ankle fracture 2.5 months prior. Therefore, she was predisposed to prolonged immobilization. Apart from acquired thrombophilic risk factors, AT and protein C levels were simultaneously reduced in the 2 episodes of PE and heterozygosity for the SERPINC1 gene was detected by mutational analysis. However, the PROC mutation was not detected by direct sequencing, even though the protein C level was reduced. The direct sequencing method is known to have PROC gene coverage of over 99%. Our patient had multiple risk factors including prolonged immobilization, inherited AT deficiency, and protein C deficiency. There are some anecdotal reports of combined AT and protein C deficiency [9, 10].

Of interest is that the patient initially presented with right abdominal pain; this is extremely rare in children.

Table 1. Thrombophilic screening tests.

| Parameters                        | 1st event | 2nd event | Normal value |
|----------------------------------|-----------|-----------|--------------|
| Prothrombin time                 | 1.08      | 1.16      | 0.9-1.24     |
| Activated partial thromboplastin time (aPTT) | 42.1      | 39.9      | 24.6-38.4    |
| Fibrinogen, mg/dL                | 690       | 334       | 200-450      |
| Fibrin degradation product, μg/mL | 14.94     | 99.15     | 0-5          |
| AT III activity, %               | 51        | 51        | 80-120       |
| Protein C antigen, %             | 18        | 30        | 72-160       |
| Protein S antigen (total), %     | 95        | 78        | 60-150       |
| Homocysteine, μmol/L             | 9.7       | NA        | 4.2-15.3     |
| Lupus anticoagulant, Positive    | (1:1.28)  | Negative  | Negative     |

Abbreviations: aPTT, activated partial thromboplastin time; AT, antithrombin; INR, International Normalized Ratio; NA, not applicable.

![Fig. 2.](bloodresearch.or.kr)
Letters to the Editor

and even adults with PE. Although the patient had multifocal thrombosis involving the right popliteal region, right common iliac, and inferior vena cava, her abdominal pain was more likely to be caused by diaphragmatic pleurisy due to right lower lobe consolidation. The most common complaint in teenagers with PE has been found to be pleuritic chest pain, in addition to cough, fever, and hemoptysis [11].

As there are a limited number of randomized control studies pertaining to the treatment duration for pediatric VTE, current recommendations are derived from case series or are extrapolated from adult data. In the case of provoked VTE, anticoagulation for 3 months is recommended. In comparison, longer duration of anticoagulation is recommended in idiopathic VTE. The recommended duration of anticoagulation in the first episode of VTE in a patient with thrombophilia is 3 months. However, indefinite anticoagulation is recommended for recurrences unless there is a high risk of bleeding problem. Therefore, in the case of a second VTE event, as in our patient, the recommended duration of anticoagulation is currently indefinite [12]. In spite of the lack of evidence, we concluded that prolonged or life-long anticoagulation could be helpful to prevent repeated VTE and/or stroke events in this patient.

Eun Sil Park, Jae Young Cho, Ji-Hyun Seo, Jae Young Lim, Hee-Shang Youn, Hyang-Ok Woo

Department of Pediatrics, Health Science Institute, Gyeongsang National University College of Medicine, Jinju, Korea

Correspondence to: Hyang-Ok Woo
Department of Pediatrics, Health Science Institute, Gyeongsang National University College of Medicine, 816 Jinju-daero, Jinju 52727, Korea
E-mail: howoo@gnu.ac.kr

Received on Mar. 21, 2017; Revised on Jun. 21, 2017; Accepted on Jul. 19, 2017
https://doi.org/10.5045/br.2018.53.1.81

Acknowledgments
This study was supported by a grant from the Development Fund Foundation, Gyeongsang National University, 2015.

Authors’ Disclosures of Potential Conflicts of Interest
No potential conflicts of interest relevant to this article were reported.

REFERENCES
1. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83:1251-7.
2. Nowak-Göttl U, Janssen V, Manner D, Kenet G. Venous thromboembolism in neonates and children-update 2013. Thromb Res 2013;131(Suppl 1):S39-41.
3. Klaassen IL, van Ommen CH, Middeldorp S. Manifestations and clinical impact of pediatric inherited thrombophilia. Blood 2015;125:1073-7.
4. van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001;139:676-81.
5. Tuckuviene R, Christensen AL, Helgestad J, Johnsen SP, Kristensen SR. Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study. J Pediatr 2011;159:663-9.
6. Parnai MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008;14:1229-39.
7. Emmerich J, Vidaud D, Alhenc-Gelas M, et al. Three novel mutations of antithrombin inducing high-molecular-mass compounds. Arterioscler Thromb 1994;14:1958-65.
8. Jochmans K, Lissens W, Yin T, et al. Molecular basis for type 1 antithrombin deficiency: identification of two novel point mutations and evidence for a de novo splice site mutation. Blood 1994;84:3742-8.
9. Gouault-Heilmann M, Quetin P, Dreyfus M, et al. Massive thrombosis of venous cerebral sinuses in a 2-year-old boy with a combined inherited deficiency of antithrombin III and protein C. Thromb Haemost 1994;72:782-3.
10. Sansores-García L, Majluf-Cruz A. Arterial and venous thrombosis associated to combined deficiency of protein C and antithrombin III. Am J Hematol 1998;57:182-3.
11. Sethuraman U, Siadat M, Lepak-Hitch CA, Haritos D. Pulmonary embolism presenting as acute abdomen in a child and adult. Am J Emerg Med 2009;27:514.e1-5.
12. Kerlin BA. Current and future management of pediatric venous thromboembolism. Am J Hematol 2012;87(Suppl 1):S68-74.